I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback